Carfilzomib

USES OF CARFILZOMIB

• Relapsed or refractory multiple myeloma – used when patients have received prior therapies.

• Combination therapy – often given with: Dexamethasone (Kd regimen), Lenalidomide and dexamethasone (KRd regimen)

• Effective in bortezomib-resistant patients – works in cases where first-generation proteasome inhibitors fail.

• Investigational uses – being studied for other hematologic cancers and some solid tumors.

• Advantage over older therapies – more potent proteasome inhibition with lower risk of peripheral neuropathy.

BRAND NAMES

Carfilzomib is marketed primarily under the brand name Kyprolis, developed by Amgen. It is the most widely recognized formulation of this drug and is used in the treatment of multiple myeloma, typically administered intravenously in clinical settings.

MECHANISM OF ACTION

Carfilzomib works by selectively and irreversibly inhibiting the proteasome, a protein complex responsible for breaking down damaged or unneeded proteins inside cells. By blocking this system, it causes an accumulation of proteins within cancer cells, leading to cellular stress and disruption of normal cell function.

PHARMACOKINETICS

Absorption

Carfilzomib is administered intravenously, so it is rapidly and completely absorbed directly into the bloodstream, bypassing the gastrointestinal tract.

Distribution

Carfilzomib has a relatively large volume of distribution (approximately 28–32 L), indicating moderate distribution into body tissues beyond the bloodstream.

Metabolism

Carfilzomib is primarily metabolized through extrahepatic pathways, mainly by peptidase cleavage and epoxide hydrolysis, rather than the cytochrome P450 enzyme system.

Excretion

Carfilzomib is mainly excreted as inactive metabolites through the urine, with only a small amount eliminated unchanged.

PHARMACODYNAMICS

Carfilzomib is a proteasome inhibitor that blocks protein degradation in cancer cells, leading to stress and apoptosis. Its effect is dose-dependent, with greater proteasome inhibition causing more cancer cell death.

ADMINISTRATION

Carfilzomib is administered intravenously, typically in a hospital or clinic setting, following a prescribed dosing schedule for multiple myeloma treatment.

DOSAGE AND STRENGTH

Carfilzomib is available in 10 mg, 30 mg, and 60 mg vials for intravenous use. The typical dosage varies based on body surface area, treatment cycle, and combination with other drugs, but a common regimen is 20–56 mg/m² administered on specific days of a 28-day cycle.

FOOD INTERACTIONS

Carfilzomib has no known significant food interactions because it is given intravenously, bypassing the gastrointestinal tract, so food intake does not affect its absorption or effectiveness.

DRUG INTERACTIONS

• Strong CYP3A inducers (e.g., rifampin, phenytoin) may slightly reduce its effectiveness, though metabolism is mostly non-CYP.

• Other cardiotoxic or nephrotoxic drugs can increase the risk of heart or kidney side effects.

• Anticoagulants may increase bleeding risk when used with carfilzomib.

CONTRAINDICATIONS

• Known hypersensitivity to carfilzomib or any of its components

• Severe cardiac conditions, such as recent myocardial infarction or uncontrolled heart failure

• Severe pulmonary hypertension or respiratory compromise

• Severe hepatic impairment (caution advised, depending on guidelines)

SIDE EFFECTS

• Hematologic: anemia, thrombocytopenia, neutropenia

• Cardiovascular: heart failure, hypertension, arrhythmias

• Respiratory: shortness of breath, pulmonary hypertension

• Gastrointestinal: nausea, diarrhea, vomiting

OVERDOSE

1.cardiac toxicity

2. severe cytopenia

3. organ dysfunction

TOXICITY

Carfilzomib toxicity mainly affects the heart, blood cells, and kidneys. High doses can cause heart failure, severe cytopenias, and kidney injury, so careful monitoring and dose adjustments are essential.